Bandaram Pharma Packtech (524602) 주식 개요반다람 파마 팩텍은 인도에서 제지 산업을 운영하고 있습니다. 자세히 보기524602 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적4/6재무 건전성3/6배당2/6강점지난 1년간 수익이 27.9% 증가했습니다.위험 분석의미 있는 시가총액이 없습니다(₹355M)이자 지급액이 수익으로 잘 충당되지 않음0.34% 의 배당금은 잉여현금흐름으로 잘 충당되지 않습니다.지난 3개월 동안 주가 변동성이 Indian 시장과 비교해 높았습니다.+ 위험 1건 추가모든 위험 점검 보기524602 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹29.5855.3% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m2b2016201920222025202620282031Revenue ₹2.0bEarnings ₹39.9mAdvancedSet Fair ValueView all narrativesBandaram Pharma Packtech Limited 경쟁사Abril Paper TechSymbol: BSE:544500Market cap: ₹303.3mKay Power and PaperSymbol: BSE:530255Market cap: ₹373.5mMohit Paper MillsSymbol: BSE:530169Market cap: ₹404.6mSundaram Multi PapSymbol: BSE:533166Market cap: ₹663.4m가격 이력 및 성과Bandaram Pharma Packtech 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹29.5852주 최고가₹49.7052주 최저가₹22.00베타-0.841개월 변동2.21%3개월 변동-0.24%1년 변동-24.15%3년 변동-61.38%5년 변동n/aIPO 이후 변동-43.12%최근 뉴스 및 업데이트공시 • 5hBandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Market cap is less than US$10m (₹370.0m market cap, or US$3.87m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m).Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹28.65, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 23x in the Forestry industry in India. Total returns to shareholders of 8.5% over the past three years.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹27.15, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 26x in the Forestry industry in India. Total returns to shareholders of 7.9% over the past three years.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.공시 • Feb 03Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026더 많은 업데이트 보기Recent updates공시 • 5hBandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Market cap is less than US$10m (₹370.0m market cap, or US$3.87m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m).Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹28.65, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 23x in the Forestry industry in India. Total returns to shareholders of 8.5% over the past three years.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹27.15, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 26x in the Forestry industry in India. Total returns to shareholders of 7.9% over the past three years.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.공시 • Feb 03Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹31.39, the stock trades at a trailing P/E ratio of 64x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 31% over the past three years.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹26.53, the stock trades at a trailing P/E ratio of 54.1x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 11% over the past three years.New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$10m (₹396.0m market cap, or US$4.43m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹403m revenue, or US$4.5m).Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹33.00, the stock trades at a trailing P/E ratio of 67.3x. Average trailing P/E is 29x in the Forestry industry in India. Total returns to shareholders of 171% over the past three years.Reported Earnings • Nov 15Second quarter 2026 earnings releasedSecond quarter 2026 results: EPS: ₹0.03. Revenue: ₹137.3m (up 93% from 2Q 2025). Net income: ₹331.0k (down 95% from 2Q 2025). Profit margin: 0.2% (down from 9.5% in 2Q 2025). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹27.49, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 35x in the Forestry industry in India. Total loss to shareholders of 39% over the past year.공시 • Nov 08Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Nov 13, 2025Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025Board Change • Sep 11High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Mounika Pammi was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Declared Dividend • Sep 08Dividend of ₹0.10 announcedDividend of ₹0.10 is the same as last year. Ex-date: 22nd September 2025 Payment date: 28th October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 37% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Sep 05Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025, at 11:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.15 in 1Q 2025)First quarter 2026 results: EPS: ₹0.01 (down from ₹0.15 in 1Q 2025). Revenue: ₹81.0m (down 29% from 1Q 2025). Net income: ₹247.0k (down 86% from 1Q 2025). Profit margin: 0.3% (down from 1.6% in 1Q 2025). The decrease in margin was driven by lower revenue.공시 • Aug 09Bandaram Pharma Packtech Limited to Report Q1, 2026 Results on Aug 14, 2025Bandaram Pharma Packtech Limited announced that they will report Q1, 2026 results on Aug 14, 2025공시 • Jul 21Bandaram Pharma Packtech Limited Appoints Mounika Pammi as Independent DirectorBandaram Pharma Packtech Limited at its EGM held on July 21, 2025 announced the appointment of Mrs. Mounika Pammi (Din: 11111376) as an independent director of the company.공시 • Jun 20Bandaram Pharma Packtech Limited Approves the Resignation of Prateek Vijayvargiya as Independent Director, Effective from June 20, 2025Bandaram Pharma Packtech Limited at its board meeting held on June 20, 2025, approved the resignation of Mr. Prateek Vijayvargiya, Independent Director of the Company effective from June 20, 2025, due to his professional commitments. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter.Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.83 (vs ₹0.79 in FY 2024)Full year 2025 results: EPS: ₹0.83 (up from ₹0.79 in FY 2024). Revenue: ₹370.6m (up 8.7% from FY 2024). Net income: ₹9.94m (up 4.9% from FY 2024). Profit margin: 2.7% (down from 2.8% in FY 2024). The decrease in margin was driven by higher expenses.New Risk • May 27New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹464.4m market cap, or US$5.44m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.0% net profit margin). Revenue is less than US$5m (₹421m revenue, or US$4.9m).Valuation Update With 7 Day Price Move • Apr 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹37.24, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 22x in the Forestry industry in India. Total returns to shareholders of 12% over the past year.Reported Earnings • Feb 19Third quarter 2025 earnings released: ₹0.01 loss per share (vs ₹0.46 profit in 3Q 2024)Third quarter 2025 results: ₹0.01 loss per share (down from ₹0.46 profit in 3Q 2024). Revenue: ₹100.0m (up 2.1% from 3Q 2024). Net loss: ₹134.0k (down 102% from profit in 3Q 2024).New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (27% accrual ratio). Market cap is less than US$10m (₹529.2m market cap, or US$6.09m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹356m revenue, or US$4.1m).Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹50.38, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 27x in the Forestry industry in India. Total returns to shareholders of 65% over the past year.Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹49.01, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 33x in the Forestry industry in India. Total returns to shareholders of 68% over the past year.공시 • Sep 13Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024, at 11:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Sep 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹37.96, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 37% over the past year.Declared Dividend • Sep 07Dividend of ₹0.10 announcedDividend of ₹0.10 is the same as last year. Ex-date: 20th September 2024 Payment date: 27th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 56% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Sep 05+ 2 more updatesBandaram Pharma Packtech Limited to Report Q2, 2025 Results on Nov 14, 2024Bandaram Pharma Packtech Limited announced that they will report Q2, 2025 results on Nov 14, 2024공시 • Sep 04Bandaram Pharma Packtech Limited Proposes Final Dividend for the Financial Year 2023-24Bandaram Pharma Packtech Limited announced that the Board of Directors at its meeting held on September 04, 2024 considered to pay Dividend of INR 0.10 per share to the shareholders, subject to approval of shareholders for the Financial Year 2023-24.Valuation Update With 7 Day Price Move • Aug 27Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₹42.44, the stock trades at a trailing P/E ratio of 47.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 53% over the past year.Reported Earnings • Aug 17First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹0.15. Revenue: ₹113.7m (up 94% from 1Q 2024). Net income: ₹1.78m (up 139% from 1Q 2024). Profit margin: 1.6% (up from 1.3% in 1Q 2024). The increase in margin was driven by higher revenue.공시 • Aug 07Bandaram Pharma Packtech Limited to Report Q1, 2025 Results on Aug 13, 2024Bandaram Pharma Packtech Limited announced that they will report Q1, 2025 results on Aug 13, 2024공시 • Jul 12Bandaram Pharma Packtech Limited Announces of Demise Bhandaram Muniratnam Reddy as Promoter/ Chairman & Non-Executive DirectorBandaram Pharma Packtech Limited announced sudden and untimely demise of Mr. Bhandaram Muniratnam Reddy (DIN: 09487708), Promoter/Chairman & Non-Executive Director of the Company on late hours of July 11, 2024. As an interim arrangement, the Management Team & Board of Directors shall continue the operations of the Company seamlessly.Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹0.82 (vs ₹0.86 in FY 2023)Full year 2024 results: EPS: ₹0.82. Revenue: ₹341.1m (up 82% from FY 2023). Net income: ₹9.68m (up 276% from FY 2023). Profit margin: 2.8% (up from 1.4% in FY 2023). The increase in margin was driven by higher revenue.공시 • May 17Bandaram Pharma Packtech Limited to Report Q4, 2024 Results on May 29, 2024Bandaram Pharma Packtech Limited announced that they will report Q4, 2024 results on May 29, 2024Valuation Update With 7 Day Price Move • Apr 01Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹35.21, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 17x in the Forestry industry in India.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹35.66, the stock trades at a trailing P/E ratio of 45.3x. Average trailing P/E is 17x in the Forestry industry in India. Total returns to shareholders of 41% over the past year.Board Change • Jan 29High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jan 01High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Oct 29Bandaram Pharma Packtech Limited to Report Q2, 2024 Results on Nov 14, 2023Bandaram Pharma Packtech Limited announced that they will report Q2, 2024 results on Nov 14, 2023공시 • Oct 18Bandaram Pharma Packtech Limited Approves Appointment of Priyanka Agarwal as an Additional Director (Independent Category)Bandaram Pharma Packtech Limited announced that at its board meeting held on October 17, 2023, approved the appointment of Ms. Priyanka Agarwal as an additional director (Independent category) of the company with effect from October 17, 2023. She is a Commerce Graduate and also completed executive course of ICSI.공시 • Sep 03Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023.공시 • Sep 02Bandaram Pharma Packtech Limited Approves Management ChangesBandaram Pharma Packtech Limited at its Board meeting held on September 01, 2023 approved Appointment of Ms. Neha Kankariya as Company Secretary and Compliance Officer of theCompany with effect from, September 01, 2023. Ms. Neha Kankariya is a qualified Company Secretary having experience of more than 5 years in Listed Companies and having soundexposure in secretarial and legal matters. Resignation of Ms. Aakanksha as an Independent Director of the Company with effect from, September 01, 2023. Appointment of Mr. Suman Mallu as an Additional Director of the Company with effect from, September 01, 2023 in Independent category. Mr. Suman Mallu is a senior architect in Bosch Limited an automotive Industry. He is having a rich experience of more than 14 years in this field.공시 • Sep 01Bandaram Pharma Packtech Limited Announces Resignation of Harish Sharma as Company Secretary and Compliance OfficerBandaram Pharma Packtech Limited announced that Mr. Harish Sharma has resigned from the post of Company Secretary and Compliance officer due to his personal reasons with effect from August 31, 2023 (close of Business hours).공시 • Aug 05Bandaram Pharma Packtech Limited to Report Q1, 2024 Results on Aug 11, 2023Bandaram Pharma Packtech Limited announced that they will report Q1, 2024 results on Aug 11, 2023New Risk • Aug 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 300% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Shares are highly illiquid. High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (300% increase in shares outstanding). Market cap is less than US$10m (₹335.6m market cap, or US$4.05m). Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (₹189m revenue, or US$2.3m).Board Change • Jul 24Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jul 03Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • May 31Bandaram Pharma Packtech Limited Recommends DividendBandaram Pharma Packtech Limited recommended a dividend of INR 0.10 (10 paisa) per share subject to approval of members at the upcoming Annual General Meeting.공시 • May 26Bandaram Pharma Packtech Limited to Report Q4, 2023 Results on May 30, 2023Bandaram Pharma Packtech Limited announced that they will report Q4, 2023 results on May 30, 2023Board Change • May 08Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 10Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Feb 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Feb 08Bandaram Pharma Packtech Limited Announces Executive ChangesBandaram Pharma Packtech Limited announces Change in designation of Mr. B. Muniratnam Reddy from Managing Director to Non-Executive Chairman of the Company. Appointment of Mr. B. Deepak Reddy as Additional director and Managing Director (Executive Category) of the Company. Appointment of Ms. Aakanksha as additional director (Independent Category) of the Company.공시 • Jan 25Bandaram Pharma Packtech Limited to Report Q3, 2023 Results on Feb 01, 2023Bandaram Pharma Packtech Limited announced that they will report Q3, 2023 results on Feb 01, 2023Board Change • Nov 22Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Venkata Rajaram Chittuluru was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률524602IN ForestryIN 시장7D2.3%-1.9%0.5%1Y-24.2%-9.3%-0.7%전체 주주 수익률 보기수익률 대 산업: 524602은 지난 1년 동안 -9.3%의 수익을 기록한 Indian Forestry 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 524602은 지난 1년 동안 -0.7%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is 524602's price volatile compared to industry and market?524602 volatility524602 Average Weekly Movement9.1%Forestry Industry Average Movement6.7%Market Average Movement7.2%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%안정적인 주가: 524602의 주가는 지난 3개월 동안 Indian 시장보다 변동성이 컸습니다.시간에 따른 변동성: 524602의 주간 변동성(9%)은 지난 1년 동안 안정적이었지만 Indian 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트199321Bandaram Reddywww.bandaram.com반다람 파마 팩텍은 인도에서 제지 산업을 운영하고 있습니다. 이 회사는 재활용 종이의 가공 및 공급, 종이 거래에 종사하고 있습니다. 주로 안드라프라데시의 동부 및 서부 고다바리 지역에 위치한 중소 규모의 제지 공장에 다양한 종류의 재활용 종이를 공급합니다.더 보기Bandaram Pharma Packtech Limited 기초 지표 요약Bandaram Pharma Packtech의 순이익과 매출은 시가총액과 어떻게 비교됩니까?524602 기초 통계시가총액₹354.96m순이익 (TTM)₹9.05m매출 (TTM)₹458.07m39.2x주가수익비율(P/E)0.8x주가매출비율(P/S)524602는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표524602 손익계산서 (TTM)매출₹458.07m매출원가₹383.00m총이익₹75.07m기타 비용₹66.03m순이익₹9.05m최근 보고된 실적Dec 31, 2025다음 실적 발표일May 30, 2026주당순이익(EPS)0.75총이익률16.39%순이익률1.98%부채/자본 비율137.4%524602의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당0.3%현재 배당 수익률21%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 23:00종가2026/05/21 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bandaram Pharma Packtech Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • 5hBandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Market cap is less than US$10m (₹370.0m market cap, or US$3.87m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m).
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹28.65, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 23x in the Forestry industry in India. Total returns to shareholders of 8.5% over the past three years.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹27.15, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 26x in the Forestry industry in India. Total returns to shareholders of 7.9% over the past three years.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
공시 • Feb 03Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026
공시 • 5hBandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Market cap is less than US$10m (₹370.0m market cap, or US$3.87m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m).
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹28.65, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 23x in the Forestry industry in India. Total returns to shareholders of 8.5% over the past three years.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹27.15, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 26x in the Forestry industry in India. Total returns to shareholders of 7.9% over the past three years.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
공시 • Feb 03Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹31.39, the stock trades at a trailing P/E ratio of 64x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 31% over the past three years.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹26.53, the stock trades at a trailing P/E ratio of 54.1x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 11% over the past three years.
New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$10m (₹396.0m market cap, or US$4.43m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹403m revenue, or US$4.5m).
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹33.00, the stock trades at a trailing P/E ratio of 67.3x. Average trailing P/E is 29x in the Forestry industry in India. Total returns to shareholders of 171% over the past three years.
Reported Earnings • Nov 15Second quarter 2026 earnings releasedSecond quarter 2026 results: EPS: ₹0.03. Revenue: ₹137.3m (up 93% from 2Q 2025). Net income: ₹331.0k (down 95% from 2Q 2025). Profit margin: 0.2% (down from 9.5% in 2Q 2025). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹27.49, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 35x in the Forestry industry in India. Total loss to shareholders of 39% over the past year.
공시 • Nov 08Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Nov 13, 2025Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025
Board Change • Sep 11High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Mounika Pammi was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Declared Dividend • Sep 08Dividend of ₹0.10 announcedDividend of ₹0.10 is the same as last year. Ex-date: 22nd September 2025 Payment date: 28th October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 37% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Sep 05Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025, at 11:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.15 in 1Q 2025)First quarter 2026 results: EPS: ₹0.01 (down from ₹0.15 in 1Q 2025). Revenue: ₹81.0m (down 29% from 1Q 2025). Net income: ₹247.0k (down 86% from 1Q 2025). Profit margin: 0.3% (down from 1.6% in 1Q 2025). The decrease in margin was driven by lower revenue.
공시 • Aug 09Bandaram Pharma Packtech Limited to Report Q1, 2026 Results on Aug 14, 2025Bandaram Pharma Packtech Limited announced that they will report Q1, 2026 results on Aug 14, 2025
공시 • Jul 21Bandaram Pharma Packtech Limited Appoints Mounika Pammi as Independent DirectorBandaram Pharma Packtech Limited at its EGM held on July 21, 2025 announced the appointment of Mrs. Mounika Pammi (Din: 11111376) as an independent director of the company.
공시 • Jun 20Bandaram Pharma Packtech Limited Approves the Resignation of Prateek Vijayvargiya as Independent Director, Effective from June 20, 2025Bandaram Pharma Packtech Limited at its board meeting held on June 20, 2025, approved the resignation of Mr. Prateek Vijayvargiya, Independent Director of the Company effective from June 20, 2025, due to his professional commitments. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter.
Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.83 (vs ₹0.79 in FY 2024)Full year 2025 results: EPS: ₹0.83 (up from ₹0.79 in FY 2024). Revenue: ₹370.6m (up 8.7% from FY 2024). Net income: ₹9.94m (up 4.9% from FY 2024). Profit margin: 2.7% (down from 2.8% in FY 2024). The decrease in margin was driven by higher expenses.
New Risk • May 27New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹464.4m market cap, or US$5.44m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.0% net profit margin). Revenue is less than US$5m (₹421m revenue, or US$4.9m).
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹37.24, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 22x in the Forestry industry in India. Total returns to shareholders of 12% over the past year.
Reported Earnings • Feb 19Third quarter 2025 earnings released: ₹0.01 loss per share (vs ₹0.46 profit in 3Q 2024)Third quarter 2025 results: ₹0.01 loss per share (down from ₹0.46 profit in 3Q 2024). Revenue: ₹100.0m (up 2.1% from 3Q 2024). Net loss: ₹134.0k (down 102% from profit in 3Q 2024).
New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (27% accrual ratio). Market cap is less than US$10m (₹529.2m market cap, or US$6.09m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹356m revenue, or US$4.1m).
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹50.38, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 27x in the Forestry industry in India. Total returns to shareholders of 65% over the past year.
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹49.01, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 33x in the Forestry industry in India. Total returns to shareholders of 68% over the past year.
공시 • Sep 13Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024, at 11:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹37.96, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 37% over the past year.
Declared Dividend • Sep 07Dividend of ₹0.10 announcedDividend of ₹0.10 is the same as last year. Ex-date: 20th September 2024 Payment date: 27th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 56% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Sep 05+ 2 more updatesBandaram Pharma Packtech Limited to Report Q2, 2025 Results on Nov 14, 2024Bandaram Pharma Packtech Limited announced that they will report Q2, 2025 results on Nov 14, 2024
공시 • Sep 04Bandaram Pharma Packtech Limited Proposes Final Dividend for the Financial Year 2023-24Bandaram Pharma Packtech Limited announced that the Board of Directors at its meeting held on September 04, 2024 considered to pay Dividend of INR 0.10 per share to the shareholders, subject to approval of shareholders for the Financial Year 2023-24.
Valuation Update With 7 Day Price Move • Aug 27Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₹42.44, the stock trades at a trailing P/E ratio of 47.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 53% over the past year.
Reported Earnings • Aug 17First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹0.15. Revenue: ₹113.7m (up 94% from 1Q 2024). Net income: ₹1.78m (up 139% from 1Q 2024). Profit margin: 1.6% (up from 1.3% in 1Q 2024). The increase in margin was driven by higher revenue.
공시 • Aug 07Bandaram Pharma Packtech Limited to Report Q1, 2025 Results on Aug 13, 2024Bandaram Pharma Packtech Limited announced that they will report Q1, 2025 results on Aug 13, 2024
공시 • Jul 12Bandaram Pharma Packtech Limited Announces of Demise Bhandaram Muniratnam Reddy as Promoter/ Chairman & Non-Executive DirectorBandaram Pharma Packtech Limited announced sudden and untimely demise of Mr. Bhandaram Muniratnam Reddy (DIN: 09487708), Promoter/Chairman & Non-Executive Director of the Company on late hours of July 11, 2024. As an interim arrangement, the Management Team & Board of Directors shall continue the operations of the Company seamlessly.
Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹0.82 (vs ₹0.86 in FY 2023)Full year 2024 results: EPS: ₹0.82. Revenue: ₹341.1m (up 82% from FY 2023). Net income: ₹9.68m (up 276% from FY 2023). Profit margin: 2.8% (up from 1.4% in FY 2023). The increase in margin was driven by higher revenue.
공시 • May 17Bandaram Pharma Packtech Limited to Report Q4, 2024 Results on May 29, 2024Bandaram Pharma Packtech Limited announced that they will report Q4, 2024 results on May 29, 2024
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹35.21, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 17x in the Forestry industry in India.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹35.66, the stock trades at a trailing P/E ratio of 45.3x. Average trailing P/E is 17x in the Forestry industry in India. Total returns to shareholders of 41% over the past year.
Board Change • Jan 29High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jan 01High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Oct 29Bandaram Pharma Packtech Limited to Report Q2, 2024 Results on Nov 14, 2023Bandaram Pharma Packtech Limited announced that they will report Q2, 2024 results on Nov 14, 2023
공시 • Oct 18Bandaram Pharma Packtech Limited Approves Appointment of Priyanka Agarwal as an Additional Director (Independent Category)Bandaram Pharma Packtech Limited announced that at its board meeting held on October 17, 2023, approved the appointment of Ms. Priyanka Agarwal as an additional director (Independent category) of the company with effect from October 17, 2023. She is a Commerce Graduate and also completed executive course of ICSI.
공시 • Sep 03Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023.
공시 • Sep 02Bandaram Pharma Packtech Limited Approves Management ChangesBandaram Pharma Packtech Limited at its Board meeting held on September 01, 2023 approved Appointment of Ms. Neha Kankariya as Company Secretary and Compliance Officer of theCompany with effect from, September 01, 2023. Ms. Neha Kankariya is a qualified Company Secretary having experience of more than 5 years in Listed Companies and having soundexposure in secretarial and legal matters. Resignation of Ms. Aakanksha as an Independent Director of the Company with effect from, September 01, 2023. Appointment of Mr. Suman Mallu as an Additional Director of the Company with effect from, September 01, 2023 in Independent category. Mr. Suman Mallu is a senior architect in Bosch Limited an automotive Industry. He is having a rich experience of more than 14 years in this field.
공시 • Sep 01Bandaram Pharma Packtech Limited Announces Resignation of Harish Sharma as Company Secretary and Compliance OfficerBandaram Pharma Packtech Limited announced that Mr. Harish Sharma has resigned from the post of Company Secretary and Compliance officer due to his personal reasons with effect from August 31, 2023 (close of Business hours).
공시 • Aug 05Bandaram Pharma Packtech Limited to Report Q1, 2024 Results on Aug 11, 2023Bandaram Pharma Packtech Limited announced that they will report Q1, 2024 results on Aug 11, 2023
New Risk • Aug 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 300% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Shares are highly illiquid. High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (300% increase in shares outstanding). Market cap is less than US$10m (₹335.6m market cap, or US$4.05m). Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (₹189m revenue, or US$2.3m).
Board Change • Jul 24Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jul 03Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • May 31Bandaram Pharma Packtech Limited Recommends DividendBandaram Pharma Packtech Limited recommended a dividend of INR 0.10 (10 paisa) per share subject to approval of members at the upcoming Annual General Meeting.
공시 • May 26Bandaram Pharma Packtech Limited to Report Q4, 2023 Results on May 30, 2023Bandaram Pharma Packtech Limited announced that they will report Q4, 2023 results on May 30, 2023
Board Change • May 08Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 10Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Feb 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Feb 08Bandaram Pharma Packtech Limited Announces Executive ChangesBandaram Pharma Packtech Limited announces Change in designation of Mr. B. Muniratnam Reddy from Managing Director to Non-Executive Chairman of the Company. Appointment of Mr. B. Deepak Reddy as Additional director and Managing Director (Executive Category) of the Company. Appointment of Ms. Aakanksha as additional director (Independent Category) of the Company.
공시 • Jan 25Bandaram Pharma Packtech Limited to Report Q3, 2023 Results on Feb 01, 2023Bandaram Pharma Packtech Limited announced that they will report Q3, 2023 results on Feb 01, 2023
Board Change • Nov 22Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Venkata Rajaram Chittuluru was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
